About the Authors
- Gouri Yogalingam
-
Roles Data curation, Formal analysis, Investigation, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: gyogalingam@bmrn.com
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Amanda R. Luu
-
Roles Methodology
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Heather Prill
-
Roles Methodology
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Melanie J. Lo
-
Roles Methodology
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Bryan Yip
-
Roles Methodology
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- John Holtzinger
-
Roles Conceptualization, Methodology
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Terri Christianson
-
Roles Methodology, Supervision
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Mika Aoyagi-Scharber
-
Roles Conceptualization, Investigation, Project administration
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Roger Lawrence
-
Roles Supervision
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Brett E. Crawford
-
Roles Supervision
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
- Jonathan H. LeBowitz
-
Roles Conceptualization, Writing – review & editing
Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America
Competing Interests
All authors are full time employees of BioMarin Pharmaceutical Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Mika Aoyagi-Scharber, Terri M. Christianson and Jonathan H. LeBowitz, together with others, are inventors on a patent claiming compositions and methods for treating Sanfilippo type B, comprising therapeutic NAGLU-IGF2 fusion proteins (US 9,376,480 B2).